GYRE
Gyre Therapeutics, Inc. NASDAQ Listed Apr 12, 2006$8.04
After hrs
$8.04
+0.00%
Mkt Cap $779.8M
52w Low $6.57
28.2% of range
52w High $11.78
50d MA $7.62
200d MA $7.68
P/E (TTM)
138.5x
EV/EBITDA
42.4x
P/B
4.9x
Debt/Equity
0.0x
ROE
9.3%
P/FCF
-3504.3x
RSI (14)
—
ATR (14)
—
Beta
6.40
50d MA
$7.62
200d MA
$7.68
Avg Volume
94.1K
About
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | 0.06 | 0.04 | -29.5% | 7.81 | +2.2% | -3.2% | -4.0% | -2.0% | -10.2% | -12.9% | — |
| Nov 7, 2025 | AMC | 0.05 | 0.06 | +20.0% | 7.21 | +5.8% | +9.8% | +11.1% | +15.7% | +12.1% | +10.8% | — |
| Aug 11, 2025 | AMC | 0.03 | 0.02 | -33.3% | 7.07 | -5.5% | +6.9% | +16.1% | +16.3% | +15.1% | +11.0% | — |
| May 9, 2025 | AMC | 0.03 | 0.03 | +0.0% | 9.53 | -0.6% | +13.6% | +20.7% | +9.0% | +14.8% | +19.1% | — |
| Mar 17, 2025 | AMC | 0.04 | 0.01 | -75.0% | 12.28 | -6.4% | -30.2% | -16.3% | -16.8% | -20.9% | -25.0% | — |
| Nov 13, 2024 | AMC | — | 0.02 | — | 14.48 | -0.2% | -4.4% | -9.4% | -12.8% | -10.8% | -10.8% | — |
| Aug 13, 2024 | AMC | — | 0.01 | — | 10.40 | +3.7% | -4.0% | +2.7% | +4.7% | +13.1% | +12.8% | — |
| May 9, 2024 | AMC | — | 0.04 | — | 15.23 | +2.8% | -2.7% | +3.4% | +3.5% | +2.6% | +0.4% | — |
| Mar 26, 2024 | AMC | -0.60 | -0.68 | -13.6% | 16.79 | -3.5% | +4.4% | +4.1% | -5.6% | +1.2% | +2.2% | — |
| Oct 26, 2023 | AMC | -0.75 | -1.05 | -40.0% | 8.10 | -1.9% | -1.9% | -5.6% | -16.9% | -22.3% | -21.6% | — |
Recent Filings
8-K · 2.01
!!! Very High
Gyre Therapeutics, Inc. -- 8-K 2.01: Acquisition Completed
Gyre Therapeutics completed its acquisition of Cullgen Inc., expanding its therapeutic pipeline and potentially strengthening its competitive position in the biotech market.
May 4
8-K · 1.01
!! High
Gyre Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Gyre Therapeutics filed a corrected 8-K to fix a clerical error in a previously disclosed material agreement, with no substantive changes to the original filing.
Apr 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
GYRE's forward-looking statement disclaimers suggest upcoming announcements about clinical results or strategic plans, creating uncertainty around near-term catalysts and stock direction that investors should monitor closely.
Mar 23
8-K
Unknown — 8-K Filing
Gyre's IND application for MASH liver fibrosis treatment in 2026 signals progression toward clinical development in a large market, potentially validating its therapeutic approach and supporting future revenue opportunities.
Mar 12
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
GYRE's lung fibrosis revenue comes primarily from rheumatoid disease patients, and management expects this profitable disease mix to persist or expand as the drug gains market adoption in the rheumatology channel.
Mar 12
8-K · 1.01
!!! Very High
Gyre Therapeutics, Inc. -- 8-K 1.01: Merger Agreement
Gyre Therapeutics agreed to merge with Cullgen Inc. in a $300 million transaction, combining the two biopharmaceutical companies.
Mar 2
Data updated apr 25, 2026 12:50pm
· Source: massive.com